Medtronic Neuro Biz Stimulation Prospects Include Epilepsy, OCD Treatments
This article was originally published in The Gray Sheet
The potential of Medtronic's deep brain stimulation technology to treat epilepsy will be evaluated in a 10-center, 124-patient pivotal trial
You may also be interested in...
Cyberonics likely will face increased pressure to execute its long term business plan and meet rising shareholder expectations now that Medtronic's unwelcome $480 mil. acquisition proposal has been withdrawn.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.